Revance Therapeutics (RVNC)
(Real Time Quote from BATS)
$3.89 USD
+0.13 (3.46%)
Updated Jul 26, 2024 09:46 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
RVNC 3.89 +0.13(3.46%)
Will RVNC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RVNC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RVNC
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
RVNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
Other News for RVNC
Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance to Participate in Upcoming Investor Conferences
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)